BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34152427)

  • 1. Reduced bendamustine for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Kurokawa M
    Ann Hematol; 2022 Mar; 101(3):713-715. PubMed ID: 34152427
    [No Abstract]   [Full Text] [Related]  

  • 2. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
    Alnuaimi K; Lavolé J; Lascoux-Combes C; Roque Afonso AM; Sogni P; Pol S; Mallet V
    Hepatology; 2018 Jun; 67(6):2468-2470. PubMed ID: 29194671
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired Gitelman Syndrome Secondary to Bendamustine Use.
    Rogers A; Gandhi P; Bautista J; Tang J
    R I Med J (2013); 2018 Nov; 101(9):36-38. PubMed ID: 30384518
    [No Abstract]   [Full Text] [Related]  

  • 5. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
    Musto P; Fraticelli VL; Mansueto G; Madonna E; Nozza A; Andriani A; Mussetti A; Ballanti S; Bongarzoni V; Baraldi A; Patriarca F; Vincelli D; Falcone A; Derudas D; Califano C; Zambello R; Mele G; Fragasso A; Baldini L; Storti S
    Leuk Lymphoma; 2015 May; 56(5):1510-3. PubMed ID: 25651428
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
    Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
    Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine.
    Rice ML; Barreto JN; Thompson CA; Mara KC; Tosh PK; Limper AH
    Cancer Med; 2021 Aug; 10(15):5120-5130. PubMed ID: 34155819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis.
    Tefferi A; Cerquozzi S; Liaw J
    Am J Hematol; 2016 Feb; 91(2):E6-7. PubMed ID: 26587685
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
    Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
    Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
    Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
    D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
    Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
    [No Abstract]   [Full Text] [Related]  

  • 14. [II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
    Ogura M
    Gan To Kagaku Ryoho; 2012 May; 39(5):736-42. PubMed ID: 22701900
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
    Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
    Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
    Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
    Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Honda A; Taoka K; Maki H; Kurokawa M
    Ann Hematol; 2023 Jan; 102(1):243-244. PubMed ID: 36369496
    [No Abstract]   [Full Text] [Related]  

  • 20. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
    Elsoueidi R; Mulat A; Mourad H
    J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.